Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5312255 | 0.99 | SLC6A3 (0.52) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL5079934 | 0.97 | SLC6A3 (0.51) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL5308426 | 0.84 | SLC6A4 (0.50) | SLC6A3SLC6A4SLC6A2CHRM2HTR2A | |
| Hydrochloric Acid SCHEMBL5433219 | 0.84 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL871941 | 0.82 | SLC6A3 (0.53) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| SCHEMBL8040636 | 0.82 | SLC6A3 (0.53) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| SCHEMBL8606048 | 0.82 | SLC6A3 (0.53) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| SCHEMBL5087133 | 0.81 | SLC6A3 (0.63) | SLC6A3SLC6A4SLC6A2KCNH2 | |
| Hydrochloric Acid SCHEMBL5313076 | 0.81 | SLC6A3 (0.51) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| SCHEMBL7708664 | 0.80 | SLC6A3 (0.54) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653911-A2 | METHODS FOR TREATING METABOLIC SYNDROME | Abbott Laboratories (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016269-A2 | METHODS FOR TREATING METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2005-02-24 | — | — | WO | claimed |
| JP-2002535273-A | — | — | 2002-10-22 | — | — | JP | claimed |
| EP-1150672-A1 | METHOD TO AID SMOKING CESSATION | KNOLL PHARMACEUTICAL COMPANY (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2000043002-A1 | METHOD TO AID SMOKING CESSATION | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-07-27 | — | — | WO | claimed |
| WO-1995021615-A1 | USE OF ARYLCYCLOBUTYLALKYLAMINES FOR THE TREATMENT OF SEIZURES AND NEUROLOGICAL DISORDERS | KNOLL AG (DE) | 1995-08-17 | — | — | WO | claimed |
| CN-101528265-A | Inclusion complex of sibutramine and beta-cyclodextrin | SK CHEMICALS CO LTD (KR) | 2009-09-09 | — | — | CN | disclosed |
| EP-2083867-A1 | INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN | SK Chemicals, Co., Ltd. (KR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2083867-A1 | INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN | SK Chemicals, Co., Ltd. (KR) | 2009-08-05 | — | — | EP | disclosed |
| EP-1827450-A4 | METHODS FOR REDUCING THE SIDE EFFECTS ASSOCIATED WITH MIRTAZAPINE TREATMENT | CYPRESS BIOSCIENCE INC (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008063024-A1 | INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN | SK CHEMICALS CO., LTD. (KR) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063024-A1 | INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN | SK CHEMICALS CO., LTD. (KR) | 2008-05-29 | — | — | WO | disclosed |
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | ABBOTT LABORATORIES | 2008-04-03 | — | — | US | disclosed |
| WO-2002046138-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF HYDROXYLATED CYCLOBUTYLALKYLAMINES | SEPRACOR INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001051453-A1 | RACEMIC AND OPTICALLY PURE METABOLITES OF SIBUTRAMINE, THEIR PREPARATION, COMPOSITIONS COMPRISING THEM AND THEIR USE AS DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0814788-A4 | IMPROVING GLUCOSE TOLERANCE | BOOTS PHARMA INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0814788-A1 | IMPROVING GLUCOSE TOLERANCE | BOOTS PHARMACEUTICALS INC. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1995021615-A1 | USE OF ARYLCYCLOBUTYLALKYLAMINES FOR THE TREATMENT OF SEIZURES AND NEUROLOGICAL DISORDERS | KNOLL AG (DE) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995020949-A1 | IMPROVING GLUCOSE TOLERANCE | BOOTS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | GIPR, MGLL, GLP1R | SLC6A3 696/4885SLC6A4 746/4885SLC6A2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.